Table 1.
Clinical characteristics of cases in this study.
| Pulmonary arterial hypertension secondary to IPF (PAH) | IPF patients with severe fibrosis (lung transplant patients) | p value | |
|---|---|---|---|
| Clinical data | |||
| N | 15 | 37 | |
| Sex | 3 females; 12 males | 5 females; 32 males | 0.870 |
| Age (yr) (mean ± SEM) | 59.67 ± 2.90 | 58.35 ± 1.46 | 0.725 |
| Smoking in history (percent) | 26.7%(4/15) | 32.4% (12/37) | 0.683 |
| BMI (mean ± SEM) | 22.27 ± 0.60 | 22.69 ± 0.62 | 0.661 |
| Lung function | |||
| FEV1 (mean ± SEM) | 1.36 ± 0.03 | 0.86 ± 0.04 | p ≤ 0.001 |
| FVC (mean ± SEM) | 1.32 ± 0.02 | 0.99 ± 0.04 | p ≤ 0.001 |
| TLC (mean ± SEM) | 1.69 ± 0.03 | 1.41 ± 0.06 | p ≤ 0.001 |
| TLCO (mean ± SEM) | 1.94 ± 0.03 | 1.41 ± 0.07 | p ≤ 0.001 |
| Medication | |||
| Prednisolone | 100% | 100% | |
| Azathioprine | 0 | 0 | |
| N-Acetylcysteine | 100% | 100% | |
Definitions of abbreviations: PAH = pulmonary arterial hypertension; IPF = idiopathic pulmonary fibrosis; TLCO = diffusing capacity of carbon monoxide. a Significant differences between the groups: p <0.05.